Covered recipient · General Payments record
JANNA HESS
General Payments · PY2022–2024
$646.24
- Reported across 35 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $188.56 | 10 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Amgen Inc. | $44.16 | 3 |
| Medtronic, Inc. | $40.01 | 1 |
| Astellas Pharma US Inc | $30.00 | 2 |
| SHIELD THERAPEUTICS INC | $24.40 | 1 |
| Novo Nordisk AS | $20.83 | 1 |
| Sumitomo Pharma America, Inc. | $14.80 | 1 |
| Exeltis, USA Inc. | $14.36 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (10)
Sorted by paying entity, then date · as published by CMS
Program year 2024 20222023
Record-level detail is published for PY2024; earlier years are summarised in
“By program year”.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Amgen Inc. | $13.61 | 01/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1115718641 | CMS |
| Amgen Inc. | $15.13 | 04/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1115718651 | CMS |
| Amgen Inc. | $15.42 | 12/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1115718658 | CMS |
| Astellas Pharma US Inc | $15.75 | 01/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139460552 | CMS |
| Astellas Pharma US Inc | $14.25 | 10/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139551329 | CMS |
| Exeltis, USA Inc. | $14.36 | 02/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1150013647 | CMS |
| Medtronic, Inc. | $40.01 | 06/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116872197 | CMS |
| Novo Nordisk Inc | $20.83 | 02/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1108567859 | CMS |
| SHIELD THERAPEUTICS INC | $24.40 | 02/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1150120801 | CMS |
| Sumitomo Pharma America, Inc. | $14.80 | 01/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1148967295 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.